NasdaqGS:RAREBiotechs
Ultragenyx Pharmaceutical (RARE) Remains Unprofitable, but 28.5% Revenue Growth Strengthens Bullish Narratives
Ultragenyx Pharmaceutical (RARE) continues to operate at a loss, with net losses growing at a rate of 14.8% per year over the past five years and no improvement in profit margins. Despite these persistent losses, revenue is forecast to climb 28.5% per year and earnings are set to jump 81.24% annually, with expectations for RARE to reach profitability within three years. The stock is trading at $31.87, notably below its estimated fair value of $361.43, positioning it as potentially undervalued...